CURATIVE EFFECT OF SANGZHI TOTAL ALKALOID TABLETS IN THE TREATMENT OF PRE-TYPE 2 DIABETES AND ITS EFFECT ON SERUM GLUCOSE TRANSPORTER 4 AND NESFATIN-1

Ying Wang¹, Zengyang Ji^{1, *}, Jie Liu², Jiaojiao Wang¹

¹Department of Endocrinology, Changxing County Traditional Chinese Medicine Hospital, Huzhou 313100, Zhejiang Province, China- ²Department of Medical Records Room, Changxing County Traditional Chinese Medicine Hospital, Huzhou 313100, Zhejiang Province, China

Objective: To investigate the clinical efficacy of Sangzhi total alkaloid tablets in the treatment of pre-type 2 diabetes mellitus (T2DM) and the effect on serum glucose transporter 4 (GLUT4) and nesfatin-1. 

Methods: A total of 100 patients with pre-T2DM who were admitted to our hospital from June 2021 to June 2022 were selected and divided into the control group and the observation group according to the random number table method, with 50 cases in each group. Patients in the control group were given basic treatment, and patients in the observation group were treated with Sangzhi total alkaloid tablets on the basis of the control group. The clinical efficacy, TCM symptom and serological indexes were compared between the two groups, and the incidence of complications was compared between the two groups. 

Results: The total effective rate of treatment in the observation group was significantly higher than that in the control group (P<0.05). After treatment, the thoracic abdominal distention, fullness after eating, obesity, chest tightness, nausea, fatigue, limb heavy, stool viscosity scores in the observation group were strikingly lower than those before treatment and the control group (P<0.05). After treatment, the levels of FPG, HbA1c, 2h PG, and HOMA-IR in the two groups were markedly lower than those before treatment (P<0.05), and those of the observation group was obviously lower than the control group (P<0.05). After treatment, the levels of TG, TC and LDL-C in the two groups were significantly lower than those before treatment (P<0.05), and those of the observation group was significantly lower than the control group (P<0.05). After treatment, the GLUT4 level in the two groups were significantly higher than that before treatment, and that of the observation group was remarkably higher than the control group (P<0.05). The level of nesfatin-1 in the two groups were dramatically lower than that before treatment, and that of the observation group was significantly lower than the control group (P<0.05). The incidence of complications in the observation group was significantly lower than that in the control group (P<0.05). 

Conclusions: Sangzhi total alkaloid tablet has good clinical efficacy in the treatment of pre-T2DM patients, which can effectively reduce insulin resistance, increase insulin sensitivity, reduce serum nesfatin-1 level, elevate serum GLUT4 level, and alleviate clinical symptoms of patients.